Higher tumor burden in the bone marrow has been established as a risk factor for toxicity in both patients with B-ALL receiving anti-CD19-CAR-T therapy (8) and patients with multiple myeloma receiving anti-B-cell maturation antigen (BCMA)-CAR-T therapy (30, 31). This evidence concerns the gene CD19 and plasma cell myeloma.